

## AMENDMENTS TO THE CLAIMS:

Please amend claims 15, 21-24, 26, 27 and 30-32; and cancel claims 16, 17 and 25 without prejudice or disclaimer. Please add claims 57-59. This listing of claims replaces all prior versions, and listings of claims in the application.

## LISTING OF CLAIMS:

1.- 14. Cancelled.

15. (Currently Amended) A method for treating a mammalian subject for hypergastrinemia, comprising the steps of:  
———(a) administering to said subject having excess gastric acid, an agent selected from the group consisting of a histamine receptor blocker and a proton pump inhibitor; and  
———(b) administering to said subject an immunogenic composition comprising a G17 peptide of SEQ ID NO: 1 or fragment thereof to thereby lower gastrin hormone levels to treat the hypergastrinemia.

16.- 17. Cancelled.

18. (Original) The method according to claim 15, wherein the serum gastrin levels of said subject are reduced or maintained at a normal level.

19. (Original) The method according to claim 18, wherein the serum gastrin levels of said subject are reduced or maintained at less than 240 pg/mL.

20. (Original) The method according to claim 18, wherein the serum gastrin levels of said subject are reduced or maintained at less than 40 pg/mL.

21. (Currently Amended) The method ~~according to~~ of claim 18, wherein ~~said~~ gastric acid production is inhibited.

22. (Currently Amended) The method ~~according to~~ of claim ~~16~~ 15, wherein ~~said~~ the subject has side-effect is pernicious anemia, a gastric tumor, or a gastric cancer consequent to the hypergastrinemia.

23. (Currently Amended) The method ~~according to~~ of claim ~~16~~ 15, wherein ~~said~~ the subject has side-effect is a cancer selected from the group consisting of colon cancer, stomach cancer, pancreatic cancer, esophageal cancer, and liver cancer consequent to the hypergastrinemia.

24. (Currently Amended) The method ~~according to~~ of claim ~~16~~ 15, wherein said administration occurs prior to the development of ~~said side-effect~~ a consequent disease.

25. Cancelled.

26. (Currently Amended) The method ~~according to~~ of claim 15, wherein ~~said the~~ hypergastrinemia is consequent to ~~subject has~~ one or more of pernicious anemia, a gastric tumor, colon cancer, stomach cancer, pancreatic cancer, esophageal cancer, ~~or~~ and liver cancer.

27. (Currently Amended) The method ~~according to~~ of claim 15, wherein said immunogenic composition comprises said G17 peptide conjugated to an immunogenic carrier ~~and in~~ in a pharmaceutically acceptable carrier.

28. (Original) The method according to claim 15, wherein said G17 peptide fragment is linked by an amino acid spacer to an immunogenic carrier.

29. (Original) The method according to claim 28, wherein said carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, and keylimpet hemocyanin.

30. (Currently Amended) The method ~~according to~~ of claim ~~15~~ 58, wherein said blocker is selected from the group consisting of ranitidine, cimetidine, fomatidine, and nizatidine.

31. (Currently Amended) The method ~~according to~~ of claim ~~15~~ 58, wherein said inhibitor is selected from the group consisting of omeprazole, lansoprazole, and patoprazole.

32. (Currently Amended) The method ~~according to~~ of claim ~~15~~ 58, wherein said subject is administered said immunogenic composition before said agent.

33.-56. Cancelled.

57. (New) The method of claim 15, wherein the treatment reduces consequent effects of hypergastrinemia.

58. (New) The method of claim 15, comprising also administering an agent selected from among a histamine receptor blocker and a proton pump inhibitor.

59. (New) The method of claim 58, wherein the method inhibits agent-induced side effects.